A business plan focused on commercial expansion, research and development. In two years, the company created 4 new patents and registered 36 innovative products, as well as launching 37 on an international scenario.
BMG Pharma and HTL Biotechnology sign an agreement for the production of the functional ingredient underlying the patented Hyaluromimethic® technology
The latest news
Massimo Doris, CEO of Banca Mediolanum buys 2% of the share package, creating a corporate form with the company specializing in the production of new biomaterials derived from hyaluronic acid.